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oxazolidin-2-one-linked 1,2,3-triazole derivatives†
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Carlos González-Romero, a Joaquín Tamaríz-Mascarúa,c
Macario Morales-Rodríguez,b Nieves Zavala-Segoviad and Aydeé Fuentes-Benítes *a
Novel oxazolidin-2-one-linked 1,2,3-triazole derivatives (4a–k) were synthesized by straightforward and
versatile azide–enolate (3 + 2) cycloaddition. The series of compounds was screened for antifungal activity
against four filamentous fungi as well as six yeast species of Candida spp. According to their efficiency and
breadth of scope, they can be ordered as 4k > 4d > 4h > 4a, especially in relation to the activity displayed
against Candida glabrata ATCC-34138, Trichosporon cutaneum ATCC-28592 and Mucor hiemalis ATCC-
8690, i.e. compounds 4d, 4h and 4k showed excellent activity against C. glabrata (MIC 0.12, 0.25 and 0.12
μg mL−1, respectively), better than that of itraconazole (MIC 1 μg ml−1). The activity of compound 4d (MIC =
2 μg mL−1) was higher than that observed for the standard antifungal drug (MIC = 8 μg mL−1) against
Trichosporon cutaneum, while compound 4k displayed an excellent antimycotic activity against Mucor
hiemalis (MIC = 2 μg mL−1 vs. 4 μg mL−1 for itraconazole). In addition, we describe herein a novel mild and
eco-friendly synthetic protocol for obtaining β-ketosulfones (adducts to afford compounds 4a–k) from
α-brominated carbonyls in an aqueous nanomicellar medium at room temperature.
1. Introduction
Both oxazolidin-2-one1 and 1,2,3-triazole2 cores are very well-
recognized pharmacophores in the literature. They have be-
come extremely versatile in medicinal chemistry, featuring
a number of clinically used drugs (e.g. Linezolid 1 or
Tazobactam 2, Fig. 1). Consequently, several antimicrobials
based on one or the other scaffold have been reported in the
literature.3 On the other hand, the study of both cores in the
same molecule (3) as an antibacterial agent has been reported4
and patented (e.g. 3a (ref. 5) and 3b (ref. 6)). This year – 2017
– Melinta Therapeutics Inc. announced the acceptance of FDA
of the Investigational New Drug (IND) application for topical
Radezolid 3c, a second-generation oxazolidinone/triazole com-
pound discovered by Melinta scientists as a novel antibiotic
to treat serious bacterial infections.7 Curiously, antifungal ac-
tivity has not been demonstrated for these kinds of com-
pounds to the best of our knowledge.
Even though the mechanism of action of oxazolidinone8
and triazole9 cores has been described, the inhibition of
monoamine oxidase A (MAO-A)4a as well as the RNA-binding
process4g has been proposed as the mode of action for
oxazolidin-2-one-linked 1,2,3-triazole.
Due to the strong resistance of fungi to current drugs,
there is a continuous search for antifungal agents. As part of
our ongoing research, we herein describe the synthesis and
biological evaluation of novel oxazolidin-2-one-linked 1,2,3-
triazole derivatives (4).
2. Chemistry
Our initial study began by obtaining the starting materials,
azide/oxazolidin-2-one 8 and ketones 11 (Scheme 1). Firstly,
chlorine derivative 7 was synthesized (61%) by coupling
between 2-chloroethyl isocyanate 6 and benzoin 5.10 Subse-
quently, the nucleophilic substitution of 7 by the azide ion
furnished compound 8 (58%).
Ketones 11a–11g were synthesized since, unlike 11i–11j,
they are not commercially available (ketone 11h was kindly
donated by Syntex-La Roche). For these purposes, we have
developed a novel organic solvent-free synthesis of
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β-ketosulfones in an aqueous nanomicellar medium by the
concomitant use of the surfactant reagent SPGS-550-M or
‘Nok’ (now available at Sigma-Aldrich11) and sodium
p-toluenesulfinate from α-bromoketones. The surfactant na-
ture of NOK (a third generation surfactant) allows it to act as
an efficient nanoreactor in catalytic amounts. The study and
scope of this novel methodology are described in the ESI† in
greater detail. Therefore, we decided to apply such a method-
ology in the synthesis of compound 11 from 10, which in
turn was accomplished by reported protocols12 with
N-bromosuccinimide (NBS) as the bromine source.
Although Cu-catalyzed azide–alkyne cycloaddition
(CuAAC) is the conventional method for obtaining 1,2,3-
triazole moieties,13 other strategies have emerged as alterna-
tives for such a purpose. We previously reported14 a novel
synthetic protocol to achieve the efficient assembly of 1,4,5-
trisubstituted 1,2,3-triazole cores through azide–enolate
cycloaddition. In consequence, oxazolidin-2-one-linked 1,2,3-
triazole derivatives (4) were synthesized by the efficient
1,3-dipolar cycloaddition of azide/oxazolidin-2-one in the
presence of enolates prepared in situ from ketones 11 acti-
vated by DBU as the base. Table 1 summarizes these
outcomes.
3. Microbiology
Compounds 4a–k were tested for their in vitro activity against
four filamentous fungi: Aspergillus fumigatus ATCC-16907,
Trichosporon cutaneum ATCC-28592, Rhizopus oryzae ATCC-
10329 and Mucor hiemalis ATCC-8690. These compounds
were also evaluated, employing standardized microbiological
methods developed by the CLSI, against six yeast specimens:
Candida albicans ATCC-10231, Candida utilis ATCC-9226, Can-
dida tropicalis ATCC-13803, Candida parapsilopsis ATCC-22019,
Fig. 1 The novel series of compounds 4 involves the extremely
important oxazolidin-2-one and 1,2,3-triazole pharmacophoric cores.
A similar feature is found in antimicrobial oxazolidin-2-one-linked
1,2,3-triazole 3, including lead compounds 1 and 2.
Scheme 1 Reagents and conditions: (i) N2, 180 °C, 24 h. (ii) NaN3 (1.1 eq.), DMF anh., 60 °C, 12 h, N2. (iii) NBS (1.1 eq.), TsOH·H2O (1.0 eq.), MeCN,
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Candida glabrata ATCC-34138, and Candida krusei ATCC-14243.
Then, the sensitivity of the filamentous microorganisms was
determined by the microdilution M38-A method,15 and that of
the yeast fungi with the M27-A3 method.16
Such antifungal activity was compared to that of
itraconazole as the standard antifungal drug. The minimum
inhibitory concentration (MIC) values of the standard and
compounds 4a–k, expressed in micrograms per milliliter,
were determined in 96-well plates using MOPS (3-[N-
morpholino]propanesulfonic acid buffered RPMI-1640 me-
dium, Sigma-Aldrich).
4. Results and discussion
The antifungal activity of the test compounds is summa-
rized in Table 2. Compounds 4d, 4h and 4k showed ex-
cellent activity against C. glabrata (MIC 0.12, 0.25 and
0.12 μg mL−1, respectively), better than that of
itraconazole (MIC 1 μg ml−1). The activity of compound
4d (MIC = 2 μg mL−1) was higher than that observed for
the standard antifungal drug (MIC = 8 μg mL−1) against
Trichosporon cutaneum, while compound 4k displayed an
excellent antimycotic activity against Mucor hiemalis (MIC
= 2 μg mL−1 vs. 4 μg mL−1 for itraconazole). Compounds
4a, 4c and 4e proved to be moderate antifungal agents
against Aspergillus fumigatus strains. The current results
suggest that the presence of either the a-CN or p-NO2Ph
group at position 5 of the triazole cores increases the
biological activity of these compounds in both yeast and
filamentous fungi.
These outcomes can also be described by the ‘sensitivity’
parameters of yeasts, according to the breakpoints described
in the M27-A3 document (Table 3). In general, C. glabrata,
C. krusei and C. parapsilosis showed some susceptibility to
the test compounds, whereas C. albicans, C. tropicalis and
C. utilis were resistant to all of them.
Table 1 Synthesis of oxazolidin-2-one-linked 1,2,3-triazoles 4a–k from azide 8 by coupling with active ketones 11
Entrya Ketone Triazoleb (yield%)c
1 11a: R2 = Ph, R1 = SO2-p-Tol 4a (68)
2 11b: R2 = p-CH3Ph, R
1 = SO2-p-Tol 4b (61)
3 11c: R2 = p-NO2-Ph, R
1 = SO2-p-Tol 4c (74)
4 11d: R2 = m-NO2Ph, R
1 = SO2-p-Tol 4d (70)
5 11e: R2 = p-Cl-Ph, R1 = SO2-p-Tol 4e (72)
6 11f: R2 = thiophen-2-yl, R1 = SO2-p-Tol 4f (68)
7 11g: R2 = 5-chlorothiophen-2-yl, R1 = SO2-p-Tol 4g (64)
8 11h: R2 = pentyl, R1 = SO2Ph 4h (71)
9 11i: R2 = CH3, R
1 = COCH3 4i (73)
10 11j: R2 = Ph, R1 = COPh 4j (71)
11 11k: R2 = Ph, R1 = CN 4k (67)
a Reaction conditions: To a solution of compound 8 (1.0 eq.) and 11 (1.0 eq.) in DMF anh., DBU (2.0 eq.) was added. The reaction mixture was
stirred at 50–60 °C for 12–24 h. b Confirmed by 1H-NMR, 13C-NMR and MS. c Yields refer to chromatographically pure isolated compounds.
Table 2 In vitro antifungal activities of the synthetized compounds (MIC, μg mL−1)
Compound C. alb C. trop C. uti C. kru C. gla C. par M. hie A. fum T. cut R. ory
4a 8 8 8 0.5 1 8 4 2 8 16
4b 1 8 4 8 2 0.25 16 8 8 16
4c 4 8 4 0.25 4 8 16 2 8 16
4d 8 8 8 8 0.12 0.5 16 16 2 16
4e 8 8 8 8 4 8 16 4 8 16
4f 8 8 8 8 1 8 16 8 8 16
4g 8 8 8 2 2 4 16 16 8 16
4h 8 8 8 8 0.25 8 16 16 8 16
4i 8 8 8 8 2 4 16 16 8 8
4j 8 8 8 8 2 8 16 16 8 16
4k 8 8 8 0.5 0.12 8 2 16 8 16
Standarda 0.03 0.06 0.25 0.25 1 0.06 4 1 8 1
Abbreviations: C. alb., Candida albicans; C. trop., Candida tropicalis; C. uti., Candida utilis; C. kru., Candida krusei; C.gla., Candida glabrata,
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5. Conclusion
In summary, eleven oxazolidin-2-one-linked 1,2,3-triazole de-
rivatives (4a–k) were synthesized in good yields based on
azide–enolate 1,3-dipolar cycloaddition. In vitro assays dem-
onstrated that compound 4k is the most efficient antimicro-
bial agent, since it was either better than or comparable to
itraconazole against three species (C. glabrata, M. hiemalis
and T. cutaneum). The second best antimicrobial activity was
exhibited by compound 4d, which was much better than the
reference drug against two species (C. glabrata and T.
cutaneum). In consequence, these compounds can be consid-
ered as drug candidates for future complementary biological
studies. In addition, we have developed a novel organic
solvent-free synthesis of β-ketosulfones in an aqueous nano-
micellar medium. The surfactant nature of SPGS-550-M or
‘NOK’ (a third generation surfactant) allows it to act as an ef-
ficient nanoreactor in catalytic amounts. The notable advan-
tages of this methodology over those previously reported in-
clude its simplicity of handling, mild conditions, high yields,
cheap reagents and great tolerance of functional groups.
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